Pharma BD Deal Intelligence
A $1.0B upfront acquisition (plus a $4.00/share CVR) that gave Lilly a neuroscience gene-therapy platform anchored on PR001, an AAV9 therapy for GBA1-mutation Parkinson's still years from its 2030 readout. The bet has already narrowed: Lilly discontinued the other named asset, PR006 for frontotemporal dementia, after disappointing efficacy.
Lilly acquires biotechnology company Prevail Therapeutics for $1.04 billion to advance gene therapy capabilities in neuroscience
Lilly discontinued LY3884963 (FTD-GRN gene therapy from Prevail) due to lack of compelling efficacy; not a safety concern. One of three programs stopped.
PR001/LY3884961 Phase 1/2a PROPEL in GBA1-Parkinson's: ACTIVE_NOT_RECRUITING, primary completion estimated December 2030.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Lilly acquired Prevail Therapeutics for $1.0B upfront ($22.50/share in cash, ~$1.04B enterprise value) plus a non-tradeable CVR worth up to $4.00/share, closing January 22, 2021, to establish a neuroscience gene-therapy platform. The lead asset, PR001/LY3884961, is an AAV9 gene therapy for GBA1-mutation Parkinson's disease and neuronopathic Gaucher disease, evaluated in the Phase 1/2a PROPEL trial (NCT04127578) — still active (not recruiting) with primary completion now estimated December 2030. The thesis was a portfolio of clinical and preclinical neurodegeneration gene therapies, but it has narrowed: in February 2026 Lilly discontinued the PR006/LY3884963 program for frontotemporal dementia with progranulin mutations (PROCLAIM trial, NCT04408625) citing lack of compelling efficacy (no safety concern), as part of a broader cut of three pipeline programs. The deal remains a long-dated, early-/mid-stage neuro bet: the lead Parkinson's program is alive but pre-revenue with a 2030 readout, while one of the two named clinical assets has now failed.
90K US cases/yr · $7.0B Global PD Market (2024)
GBA1 variants most common genetic risk for PD (5-10%). PR001 (LY3884961) AAV9 gene therapy delivering functional GBA1 to CNS.
Lilly/Prevail (PR001), BlueRock/Bayer (Bemdaneprocel), MeiraGTx (AAV-GAD). Most programs early-stage.
PR001/LY3884961 is an AAV9 gene therapy delivering the GBA1 gene for neuronopathic Gaucher Disease (Type 2/3), targeting the CNS manifestations that current enzyme replacement therapies (ERT) cannot reach because recombinant glucocerebrosidase does not cross the blood-brain barrier. Enzyme replacement therapy (non-CNS standard): imiglucerase (Cerezyme, Sanofi), velaglucerase alfa (VPRIV, Takeda), and taliglucerase alfa (Elelyso, Pfizer) are FDA-approved for Type 1 (non-neuronopathic) Gaucher; Sanofi reported 2023 Cerezyme/Cerdelga revenues of approximately €582M combined. These are used off-label for visceral manifestations in Type 2/3 but do not address neurologic progression. Substrate reduction therapy (SRT): miglustat (Zavesca, Johnson & Johnson/generic) is FDA-approved for Type 1 and crosses the BBB but has shown modest/inconclusive CNS benefit in Type 3; eliglustat (Cerdelga, Sanofi) is approved for Type 1 but does not cross the BBB. Gene therapy (direct MOA competitor): AVR-RD-02 (AvroBio) was an autologous ex vivo lentiviral hematopoietic stem cell gene therapy for Type 1 Gaucher — AvroBio discontinued the program in 2022. Freeline Therapeutics' FLT201 is a liver-directed AAV gene therapy for Type 1 Gaucher in Phase 1/2. No approved CNS-penetrant therapy exists for Type 2/3 Gaucher — PR001/LY3884961's commercial moat is first-in-class CNS-directed gene therapy in an ultra-rare pediatric lethal disease with ERT orphan pricing benchmarks.
Eli Lilly completed $1B acquisition of Prevail Therapeutics, gaining PR001 gene therapy for GBA1-associated Parkinson's and neuronopathic Gaucher disease.
Lilly advanced PR001 through Phase 1/2 in GBA1-PD and Gaucher disease, targeting genetic subsets of neurodegeneration.
Lilly discontinued the PR006/LY3884963 PROCLAIM program (frontotemporal dementia with GRN mutations, NCT04408625) for lack of compelling efficacy; no safety concern. One of two named clinical assets from the Prevail acquisition is now dead; lead PR001 Parkinson's program (PROPEL) continues with a ~2030 readout.
PR001 represents Lilly's gene therapy neuro approach. Early/mid-stage. $1B is strategic option within larger neuroscience portfolio.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Prevail Therapeutics (this deal) | 2020 | $1.0B | 48 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2020 deals · Eli Lilly and Company deals · Metabolic deals